Selected article for: "benign prostatic hyperplasia and prostatic hyperplasia"

Author: Maximilian F Konig; Mike Powell; Verena Staedtke; Ren-Yuan Bai; David L Thomas; Nicole Fischer; Sakibul Huq; Adham M Khalafallah; Allison Koenecke; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Joshua T Vogelstein; Susan Athey; Shibin Zhou; Chetan Bettegowda
Title: Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
  • Document date: 2020_4_8
  • ID: 0lwmzjxz_5
    Snippet: To date, no controlled trials have examined the potential benefits of ⍺1-AR antagonism for the prevention of CSS and mitigation of ARDS in human subjects. To investigate a role for ⍺1-AR antagonists in preventing poor outcomes resulting from pulmonary hyperinflammatory responses, we conducted a retrospective analysis of two cohorts of 45-64 year-old hospitalized patients from the MarketScan Research Database (2007 Database ( -2015 . Some of t.....
    Document: To date, no controlled trials have examined the potential benefits of ⍺1-AR antagonism for the prevention of CSS and mitigation of ARDS in human subjects. To investigate a role for ⍺1-AR antagonists in preventing poor outcomes resulting from pulmonary hyperinflammatory responses, we conducted a retrospective analysis of two cohorts of 45-64 year-old hospitalized patients from the MarketScan Research Database (2007 Database ( -2015 . Some of these patients would be expected to be taking ⍺1-AR antagonists for the treatment of chronic conditions unrelated to ARDS such as benign prostatic hyperplasia or hypertension.

    Search related documents:
    Co phrase search for related documents
    • benign prostatic hyperplasia and poor outcome: 1
    • benign prostatic hyperplasia and prostatic hyperplasia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
    • chronic condition and control trial: 1
    • chronic condition and hyperinflammatory response: 1
    • chronic condition and retrospective analysis: 1, 2, 3
    • control trial and hospitalized patient: 1
    • control trial and human subject: 1, 2
    • control trial and poor outcome: 1
    • control trial and potential benefit: 1, 2, 3, 4, 5
    • control trial and retrospective analysis: 1, 2, 3, 4
    • hospitalized patient and hyperinflammatory response: 1
    • hospitalized patient and poor outcome: 1, 2
    • hospitalized patient and potential benefit: 1, 2
    • hospitalized patient and retrospective analysis: 1, 2, 3
    • hospitalized patient and year old hospitalized patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • human subject and retrospective analysis: 1
    • hyperinflammatory response and poor outcome: 1, 2, 3, 4
    • hyperinflammatory response and potential benefit: 1, 2
    • hyperinflammatory response and pulmonary hyperinflammatory response: 1, 2